Immunicum Doses the First Patient in a New Clinical Phase I/II-Study in Primary Liver Cancer

Gothenburg, Sweden, 2013-10-23 12:27 CEST (GLOBE NEWSWIRE) -- The first patient in Immunicum’s clinical phase I/II-study in primary liver cancer today received the initial dose of the therapeutic cancer vaccine INTUVAX®. The Company is also finalizing a clinical phase I/II-study in metastatic renal cell carcinoma, initiated in February 2012 and thus far showing promising data.

Help employers find you! Check out all the jobs and post your resume.